FI940098A0 - Menetelmiä liikehermotautien hoitamiseksi käyttäen BDNF/NT-3/NGF -molekyyliperheen jäseniä - Google Patents

Menetelmiä liikehermotautien hoitamiseksi käyttäen BDNF/NT-3/NGF -molekyyliperheen jäseniä

Info

Publication number
FI940098A0
FI940098A0 FI940098A FI940098A FI940098A0 FI 940098 A0 FI940098 A0 FI 940098A0 FI 940098 A FI940098 A FI 940098A FI 940098 A FI940098 A FI 940098A FI 940098 A0 FI940098 A0 FI 940098A0
Authority
FI
Finland
Prior art keywords
bdnf
care
procedure
movement
nervous diseases
Prior art date
Application number
FI940098A
Other languages
English (en)
Swedish (sv)
Other versions
FI940098A (fi
Inventor
Vivien Wong
Czeslaw Radziejewski
Peter Distefano
Original Assignee
Regeneron Pharma
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Max Planck Gesellschaft filed Critical Regeneron Pharma
Publication of FI940098A0 publication Critical patent/FI940098A0/fi
Publication of FI940098A publication Critical patent/FI940098A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
FI940098A 1991-07-10 1994-01-10 Menetelmiä liikehermotautien hoitamiseksi käyttäen BDNF/NT-3/NGF -molekyyliperheen jäseniä FI940098A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72770491A 1991-07-10 1991-07-10
PCT/US1992/004228 WO1993001300A1 (en) 1991-07-10 1992-05-19 Methods of treatment of motor neuron diseases using members of the bdnf/nt-3/ngf family of molecules

Publications (2)

Publication Number Publication Date
FI940098A0 true FI940098A0 (fi) 1994-01-10
FI940098A FI940098A (fi) 1994-03-10

Family

ID=24923677

Family Applications (1)

Application Number Title Priority Date Filing Date
FI940098A FI940098A (fi) 1991-07-10 1994-01-10 Menetelmiä liikehermotautien hoitamiseksi käyttäen BDNF/NT-3/NGF -molekyyliperheen jäseniä

Country Status (20)

Country Link
EP (2) EP0755682A1 (fi)
JP (1) JPH06509094A (fi)
CN (1) CN1065768C (fi)
AT (1) ATE202939T1 (fi)
AU (2) AU675409B2 (fi)
CA (1) CA2113083A1 (fi)
DE (1) DE69231930T2 (fi)
DK (1) DK0593516T3 (fi)
ES (1) ES2157903T3 (fi)
FI (1) FI940098A (fi)
GR (1) GR3036776T3 (fi)
HU (1) HUT70275A (fi)
IE (1) IE921602A1 (fi)
IL (1) IL101928A0 (fi)
NO (1) NO940084L (fi)
PT (1) PT100501A (fi)
RU (1) RU94016525A (fi)
SK (1) SK2694A3 (fi)
WO (1) WO1993001300A1 (fi)
ZA (1) ZA923639B (fi)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07509600A (ja) * 1992-06-12 1995-10-26 リジェネロン　ファーマシューティカルズ，インコーポレーテッド ニューロトロフィン−４発現に基づく治療および診断法
FR2717496B1 (fr) * 1994-03-18 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
CN1112215C (zh) * 1999-12-28 2003-06-25 潘晓东 神经生长因子在治疗有机溶剂中毒性周围神经病中的用途
CA2408255A1 (en) 2000-05-05 2001-11-15 Marie T. Filbin Methods for stimulating nervous system regeneration and repair by regulating arginase 1 and polyamine synthesis
US7691629B2 (en) * 2004-11-17 2010-04-06 Neuralstem, Inc. Transplantation of human neural cells for treatment of neurodegenerative conditions
WO2008156418A1 (en) * 2007-06-19 2008-12-24 Astrazeneca Ab A method for screening or diagnosis of postpolio syndrome and fibromyalgia
PT2187964E (pt) * 2007-08-10 2015-01-14 Regeneron Pharma Anticorpos humanos de elevada afinidade para o factor de crescimento neural humano
WO2014111525A2 (en) 2013-01-18 2014-07-24 Anaxomics Biotech, Sl New combination therapies for treating nervous system diseases
WO2016210325A1 (en) 2015-06-26 2016-12-29 C.R. Bard, Inc. Connector interface for ecg-based catheter positioning system
WO2023164311A2 (en) * 2022-02-28 2023-08-31 Bioincept, Llc Compositions and methods of treating amyotrophic lateral sclerosis (als) and related disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923696A (en) * 1987-05-04 1990-05-08 Baylor College Of Medicine Method to prepare a neurotrophic composition
GR1000980B (el) * 1989-08-30 1993-03-31 Max Planck Gesellschaft Νευροτροφινη-3,ενας νεος neυροτροφικος παραγοντας που σχετιζεται με τον παραγοντα αναπτυξης νευρων και τον νευροτροφικο παραγοντα που προερχεται απο τον εγκεφαλο.
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
IE903130A1 (en) * 1989-09-15 1991-03-27 Regeneron Pharma Ciliary neurotrophic factor

Also Published As

Publication number Publication date
WO1993001300A1 (en) 1993-01-21
EP0593516A1 (en) 1994-04-27
GR3036776T3 (en) 2002-01-31
DK0593516T3 (da) 2001-09-17
DE69231930D1 (de) 2001-08-16
RU94016525A (ru) 1996-06-10
SK2694A3 (en) 1995-02-08
CN1065768C (zh) 2001-05-16
ATE202939T1 (de) 2001-07-15
NO940084L (no) 1994-03-08
AU675409B2 (en) 1997-02-06
CN1071585A (zh) 1993-05-05
CA2113083A1 (en) 1993-01-21
IL101928A0 (en) 1992-12-30
HU9400063D0 (en) 1994-06-28
NO940084D0 (no) 1994-01-10
AU7067696A (en) 1997-01-16
DE69231930T2 (de) 2002-04-11
PT100501A (pt) 1993-09-30
ZA923639B (en) 1993-02-24
EP0755682A1 (en) 1997-01-29
AU2009592A (en) 1993-02-11
ES2157903T3 (es) 2001-09-01
EP0593516A4 (en) 1995-01-18
JPH06509094A (ja) 1994-10-13
FI940098A (fi) 1994-03-10
HUT70275A (en) 1995-09-28
EP0593516B1 (en) 2001-07-11
IE921602A1 (en) 1993-01-13

Similar Documents

Publication Publication Date Title
ATE183232T1 (de) Herstellung von biologisch aktiven rekombinanten mitgliedern der ngf/bdnf-familie neurotroper proteine
FI940098A0 (fi) Menetelmiä liikehermotautien hoitamiseksi käyttäen BDNF/NT-3/NGF -molekyyliperheen jäseniä
ATE88900T1 (de) Konjugate von interferon alpha mit immunglobulinen.
NO951592L (no) Fremgangsmåte for fremstilling av et transdermalt terapeutisk system
DE59108854D1 (de) Arzneimittel sowie deren herstellung und deren verwendung bei der bekämpfung von schmerzen und/oder entzündungen an tieren und menschen
DE59409604D1 (de) Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
DE69033703T2 (de) Nichtglykosyliertes fgf-4 und dieses enthaltende präparate
NO882853L (no) Korreksjon med dobbeltraadet rna av unormale tilstander i immunkomplekser som er i omloep, og i monocyttfunkjon.
PT533281E (pt) A utilizacao sw citrato de ranitidina bismuto e em combinacao com claritromicina ou claritromicina e tetraciclina no fabrico de um medicamento para tratamento de perturbacoes gastrointestinais
DE3782346T2 (de) Verwendung von chinolon und naphthyridin-antibiotika zur herstellung von ophthalmischen arzneimitteln.
ES2051710T3 (es) Utilizacion de d-fenfluramina para la fabricacion de medicamentos para el tratamiento de depresiones.
MD1716B2 (en) Use of melatonin for treatment of patients dependent on benzodiazepine
Aurela A systematic storytelling therapy.
Ibáñez et al. Life and death in the nervous system: role of neurotrophic factors and their receptors
ES2058555T3 (es) Medicamento para el tratamiento intralesional del carcinoma de celulas escamosas, con alfa-interferon humano recombinante.
Dienstfrey Neal Miller, the dumb autonomic nervous system, and biofeedback.
ATE151632T1 (de) Verwendung von felbamate zur herstellung eines arzneimittels zur behandlung neuropsychopharmakologischer störungen
ATE84418T1 (de) 2,6-diamino-3-phenyl-azo-pyridin enthaltendes tier- und humanarzneimittel mit antiviraler und antitumoraler aktivitaet.

Legal Events

Date Code Title Description
FD Application lapsed